On March 11, Gelonghui reported that Chongqing Lummy Pharmaceutical Co., Ltd. received the Drug Registration Certificate issued by the National Medical Products Administration for two specifications of injectable Nicorandil, 2mg and 12mg.
Injectable Nicorandil is primarily used for unstable angina and acute heart failure, improving coronary microcirculation, effectively reducing cardiovascular events, and significantly reducing the risk of acute coronary syndrome, benefiting clinical patients greatly.
Nicorandil was developed by Shinogi & Co., Ltd. The Nicorandil tablets and injectable forms were approved for marketing by Japan's Pharmaceuticals and Medical Devices Agency in 1983 and 1993, respectively. The original Nicorandil tablets were approved for marketing in China in 2005.
According to data from Yaorongyun, the sales revenue of injectable Nicorandil in Chinese hospitals (all terminals) for the years 2022 to the first half of 2024 were 1.227 billion yuan, 0.81 billion yuan, and 0.329 billion yuan, respectively.
Comment(0)
Reason For Report